Editas Medicine (EDIT) announced CFO Erick Lucera is stepping down to pursue an external opportunity, effective March 28. Current senior VP of finance Amy Parison will succeed Lucera as CFO. Parison has more than 18 years of financial, accounting, and business development experience in life sciences. During her time at Editas, she has served in multiple roles of increasing responsibilities including senior VP, finance, and VP and corporate controller.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Cautious Hold Rating on Editas Medicine Amid Early Development Stage and Long-Term Milestones
- Biotech Alert: Searches spiking for these stocks today
- Sell Rating for Editas Medicine Amid Strategic Shift and Competitive Pressures
- Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position
- Editas Medicine: Hold Rating Maintained Amid Strategic Advancements and Financial Stability
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue